NIH review cites scientists for breaking ethics rules on drug ties

A review by the NIH has concluded that 44 government scientists have violated ethics rules with their ties to pharmaceutical companies, and nine of them may have broken the law. The 44 scientists had either failed to disclose payments from drug companies, failed to get the NIH's permission to consult with them or did work for the drug companies on government time. Congressman Joe Barton said the ethical problems were "more systemic and severe than previously known."

- read this story from The New York Times for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.